DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZELAPAR

Summary for Tradename: ZELAPAR

Patents:2
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 ZELAPAR

Clinical Trials for: ZELAPAR

Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
Status: Completed Condition: Parkinson's Disease

Evaluation of Adhesion and Dermal Tolerability of EMSAM
Status: Completed Condition: Healthy

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly
Status: Completed Condition: Healthy

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Status: Completed Condition: Parkinson's Disease

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
Status: Recruiting Condition: Borderline Personality Disorder

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Status: Completed Condition: Major Depressive Disorder

Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
Status: Completed Condition: Marijuana Abuse

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
Status: Completed Condition: Cognition Disorders; HIV Infections

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
Status: Completed Condition: Cocaine Use Disorders

Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
Status: Recruiting Condition: Parkinson's Disease; Erectile Dysfunction

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479Jun 14, 2006RXYes5,648,093<disabled>Y<disabled>
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479Jun 14, 2006RXYes6,423,342<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc